Navigation Links
Study Cites Gains in Gall Bladder Cancer Treatment
Date:5/18/2009

Early detection, aggressive surgery boosts survival times, researchers say

MONDAY, May 18 (HealthDay News) -- Patients with gallbladder cancer are surviving longer than they used to, but the death rate is still high, new research shows.

An estimated 9,520 cases of gallbladder or bile duct cancer were diagnosed in the United States in 2008, and about 3,340 people died of the disease, according to the study in the May issue of the Archives of Surgery.

The death rate is high, in part, because at the time of diagnosis, many patients already have advanced-stage disease and are not candidates for surgery. Resection, where the diseased portions of the organ are removed surgically, is the only means of curing it.

"Gallbladder cancer is characterized by locally aggressive behavior, with early spread to regional lymph nodes and distant dissemination," the authors wrote. "In addition, it recurs rapidly even after presumed curative resection."

Still, survival times for the disease, which affects women more frequently than men, have improved since the 1960s.

Researchers from Harvard Medical School identified 402 patients with gallbladder cancer at a university-affiliated center between 1962 and 2008. Of these, 260 underwent surgical exploration at the same institution and were included in the data analysis.

Patients were diagnosed during three periods: period A (1962 to 1979), period B (1980 to 1997) and period C (1998 to 2008).

Overall median survival improved from 3.5 months during period A to six months in period B to one year in period C.

Survival times were the longest among those whose disease was caught early. The median survival was 10.3 months for those diagnosed with stage 2 cancer, compared to 4.7 months for stage 3 disease and 4 months for stage 4.

"The survival of patients who presented with advanced-stage disease and who underwent palliative [treating symptoms only] procedures remained poor in all periods," with patients surviving a median of 1.9 months in the 1960s and 70s to 3.6 months in recent years.

Of the 260 cancer patients who had surgery to explore the extent of their disease, about 58 percent had the cancer surgically removed. Unresectable disease became less common over time (44.4 percent in periods A and B and 17.3 percent in period C).

Between January 1994 and March 2008, 6,881 laparoscopic cholecystectomies (procedures to remove gallstones) were performed at the same facility. Gallbladder cancer was found in 17 patients incidentally during these procedures.

"When gallbladder cancer is found incidentally during or after a cholecystectomy, aggressive resection should be performed either during the present operation or during a second operation," the authors wrote. "In our series, 56 percent of patients who underwent re-exploration [a second surgery] were found to have residual disease. Patients underwent re-exploration at a median of 41 days, similar to other series."

The authors said early detection and an aggressive surgical approach was currently the most effective way of increasing survival times.

"A better understanding of the molecular pathways contributing to the development of gallbladder cancer is needed to develop improved adjuvant therapies to increase overall survival," they wrote.

More information

The U.S. National Library of Medicine has more on gallbladder and bile duct cancer.



-- Jennifer Thomas



SOURCE: Archives of Surgery, news release, May 18, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Mock CPR drills in kids show many residents fail in key skills, Hopkins study reveals
2. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
3. Study finds higher prevalence of early menarche among survivors of childhood sexual abuse
4. Study: Smoking bans do not cause job losses in bars and restaurants
5. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
6. First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing
7. Study sees transient heart dysfunction in some long-distance runners
8. Study tests the effect of ending ambulance diversion
9. Long-term study shows low oxygen levels in prostate tumors can predict recurrence
10. U.S. Study Shows Significant Improvement for Patients Suffering from Excessive Sweating with Topical Antiperspirant
11. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Cites Gains in Gall Bladder Cancer Treatment
(Date:12/2/2016)... ... ... For over twenty-four years, Doctors on Liens has published a directory of the ... medical care. When the company started in 1997, the directory was a single page ... the now ten-page directory features a vast array of medical specialists stretching from ...
(Date:12/2/2016)... ... 02, 2016 , ... FlexiSpot, a trusted name in sit-stand ... program for all of the company’s desktop riser products. A simple application form ... , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering system ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the ... how he was inspired to practice medicine at an early age by his father, ... than making diagnoses and prescribing medicine,” he states. “It is about building relationships with ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a ... in the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. ... their education, experience, and professional associations. , One the most frequently honored ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, ... through labeling, storing, shipping and disposal. The new version is a faster and ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Md. , Dec. 2, 2016 The ... indication for Jardiance (empagliflozin) to reduce the risk of ... mellitus and cardiovascular disease. "Cardiovascular disease ... type 2 diabetes mellitus," said Jean-Marc Guettier , ... Endocrinology Products in FDA,s Center for Drug Evaluation and ...
(Date:12/2/2016)... the ECG Cables And ECG Leadwires Market owing to the ... On the other hand, the Asia-Pacific ... during the forecast period. The market players namely, ... ( Ireland ), Koninklijke Philips N.V. ( ... China ), held major share of the ECG ...
(Date:12/2/2016)... , December 2, 2016 ... Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, Software), ... (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast ... is valued at USD 60.22 Billion in 2016. ... CAGR of 5.5% during the forecast period (2016-2021) ...
Breaking Medicine Technology: